Oxford Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-182,202
| Closed | -$683K | – | 2059 |
|
|
2017
Q4 | $683K | Buy |
182,202
+46,165
| +34% | +$189K | 0.01% | 1086 |
|
|
2017
Q3 | $558K | Sell |
136,037
-45,286
| -25% | -$173K | 0.01% | 1161 |
|
|
2017
Q2 | $674K | Buy |
181,323
+19,131
| +12% | +$75.9K | 0.01% | 1020 |
|
|
2017
Q1 | $671K | Buy |
162,192
+40,117
| +33% | +$169K | 0.02% | 953 |
|
|
2016
Q4 | $526K | Buy |
122,075
+108,526
| +801% | +$702K | 0.02% | 580 |
|
|
2016
Q3 | $133K | Buy |
13,549
+2,995
| +28% | +$21.2K | ﹤0.01% | 728 |
|
|
2016
Q2 | $60K | Buy |
10,554
+6,845
| +185% | +$46.5K | ﹤0.01% | 751 |
|
|
2016
Q1 | $28K | Sell |
3,709
-12,787
| -78% | -$98.5K | ﹤0.01% | 778 |
|
|
2015
Q4 | $230K | Buy |
+16,496
| New | +$284K | 0.01% | 784 |
|
|
2015
Q2 | – | Sell |
-2,894
| Closed | -$28K | – | 786 |
|
|
2015
Q1 | $28K | Sell |
2,894
-50,092
| -95% | -$491K | ﹤0.01% | 653 |
|
|
2014
Q4 | $605K | Buy |
+52,986
| New | +$575K | 0.01% | 547 |
|
|
2014
Q3 | – | Sell |
-2,886
| Closed | -$56K | – | 812 |
|
|
2014
Q2 | $56K | Sell |
2,886
-17,488
| -86% | -$309K | ﹤0.01% | 667 |
|
|
2014
Q1 | $366K | Buy |
+20,374
| New | +$335K | 0.01% | 547 |
|
|
2013
Q3 | – | Sell |
-7,500
| Closed | -$70K | – | 979 |
|
|
2013
Q2 | $70K | Buy |
+7,500
| New | +$96.3K | ﹤0.01% | 837 |
|
Oxford Asset Management's CASC Position: Q1 2018 in Review
Oxford Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 182,202 shares — an estimated $683K sold.
Oxford Asset Management first reported a position in CASC in Q2 2013 and held it in 14 quarters. The position peaked at $683K in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Oxford Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Oxford Asset Management sold 182,202 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $683K.
- Oxford Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 14 quarters.
- Oxford Asset Management's Cascadian Therapeutics, Inc. position peaked at $683K in Q4 2017.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Oxford Asset Management's 13F filing for Q1 2018, filed 15 May 2018.